Tenobon 300mg Boston medicine for HIV-1 and AIDS prevention (3 blisters x 10 tablets)

Dosage form Box of 3 blisters x 10 tablets
Specifications Tenofovir disoproxil fumarat

Ingredient

Composition information	Content
Tenofovir disoproxil fumarat	300mg

Uses

Indications

tenofovir disoproxil fumarat is used in combination with other antiviral drugs (but not used individually) in the treatment of coach-1 infection (HIV-1), AIDS.

Tenofovir disoproxil fumarat is used in combination with other antiviral drugs in HIV prevention after exposure to the disease (due to occupation or not by occupation) in individuals at risk of viral infection.

Tenofovir disoproxil fumarat is also used in the treatment of chronic hepatitis B in adults as well as adefovir, Tenofovir also has the activity against HBV virus mutant resistance to Lamivudin.

Pharmacology

Tenofovir Disoproxil Fumarat has a structure of a nucleotid diester that is similar to adenosin monophosphate. Tenofovir Disoproxil Fumarat undergoing the initial hydrolysis of Tenofovir and followed by phosphorylation by enzymes in cells to form Tenofovir Diphosphate. Tenofovir diphosphate inhibits the activity of the enzyme enzyme reverse copying HIV - 1 by competing with the natural substrate Deoxyadenosin -5 'Triphosphate and after cohesion to DNA, ending the DNA chain.

Tenofovir diphosphate is a weak inhibitor A and B-DNA polymerase of mammals and G-DNA polymerase enzymes in vertebrates.

Dynamic pharmacokinetics

After taken, Tenofovir Disoproxil Fumarat is quickly absorbed and transformed into Tenofovir, with peaks in plasma after 1-2 hours. Born is about 25% but increases when using Tenofovir Disoproxil Fumarat with a fat -rich meal.

Tenofovir is widely distributed in tissues, especially in the kidneys and liver. The cohesion of plasma proteins is lower than 1% and with serum protein about 7%.

Tenofovir waste sale time is from 12 to 18 hours. Tenofovir is excreted mainly in urine in both ways: excreted through the renal tubules and glomerular filtration. Tenofovir is eliminated by hemolysis.

Before taking Tenobon 300mg Boston medicine for HIV-1 and AIDS prevention (3 blisters x 10 tablets)

How to use

Tenoboston is used by oral, should be taken with meals at a certain time.

Dosage

HIV infection treatment: 1 tablet x 1 time/day, combined with other antiviral drugs.

Prevention of HIV -contaminated after contact due to occupational causes: 1 tablet x 1 time/day in combination with other antiviral drugs (usually combined with lamivudin or emtricitabine). Prevention should start as soon as possible after contact due to career reasons (preferably within a few hours than a few days) and continue for the next 4 weeks if tolerated.

HIV infection prevention is not due to occupational reasons: 1 tablet x 1 time/day in combination with at least 2 other antiviral drugs. Preventive should start as soon as possible after contact without career reasons (preferably within 72 hours) and continue in 28 days.

Treatment of chronic hepatitis B: The recommended dose is 1 tablet 1 time/day for more than 48 weeks.

Patients with renal failure:

Should reduce the dose with Tenofovir Disoproxil Fumarat by adjusting the duration of the drug duration in patients with renal impairment based on the patient's clearine clearance (CC) of the patient:

cc 50 ml/minute or larger: use the usual doses 1 time/day.

Due to the safety and effectiveness of these doses that have not been clinically evaluated, the clinical response of therapy and kidney function should be closely monitored.

Patients with liver failure: For patients with impaired liver function, the dose is not required.

What to do when overdose?

Symptoms: No report.

Treatment: If an overdose occurs, patients need to be monitored with signs of poisoning, it is necessary to use basic supportive treatments. Tenofovir is eliminated effectively by hemolysis with a separation coefficient of about 54%. With a single dose of 300 mg with about 10% of Tenofovir doses excluded in a 4 -hour hemolysis.

What to do when forgetting a dose?

Side Effects

Common side effects when using Tenofovir Disoproxil Fumarat are mild effects on the gastrointestinal tract such as anorexia, abdominal pain, indigestion, flatulence, nausea, vomiting.

Other side effects such as drowsiness, headache, skin rash, decreased blood lipids, hypercase plasma, pancreatitis, hyper enzyme, hepatitis, glomerulonephritis.

may experience symptoms: diabetes diabetes due to kidney, kidney damage, acute renal failure, the effect of the drug on a distance, fanconi syndrome.

Like other reverse enzyme inhibitors, Tenofovir also has the ability to enlarge and degenerate fat, leading to blood lactic acid infection.

For HIV patients with severe immune system impairment, the use of Tenofovir Disoproxil Fumarat as well as other reverse -transcendent enzyme antacids causes immune activation syndrome (clinical immune response decline).

can lead to fat metabolism disorders: abdominal fat, increase fat in the neck, destroy peripheral system, face, increase milk glands, cushing, increase triglycerides, blood cholesterol, blood glucose, blood lactate, insulin resistance, ...

Abnormal behaviors, anemia, convulsions, hyperlipidemia, muscle tension, leukemia, increased creatine phosphokinase, muscle pain, muscle inflammation, muscle pattern can occur when using enzyme inhibitors.

can lead to bone necrosis in HIV patients progressing or using long -term antiviral therapy.

Effects on the kidneys: When using the drug in HIV patients will lead to kidney damage including: fanconi symptoms, interstitial nephritis, acute nephrotic damage (due to non -recovery renal necrosis). Glomerular filtration or creatinine clearance decreases when using the drug, and reduced sharply when combined with HIV-Protease inhibitors.

Warnings

Before using the drug you need to read the instructions carefully and refer to the information below.

Contraindicated

Patients with hypersensitivity to Tenofovir Disoproxil Fumarat or any component of the drug.

Be cautious when used

Stop the drug as soon as the concentration of amino transferase increases or in the condition of progressive liver, fat degeneration, metabolism, lactic acid infection with unknown reasons.

Use cautious in large liver patients or have risk factors for liver disease, patients with hepatitis C treated with α-Interferon and Ribavirin.

For patients with kidney damage, kidney function and plasma phosphate function should be monitored before conducting treatment with Tenofovir Disoproxil Fumarat (in the first year 4 weeks/time then dropped to 3 months/time in the following years). For patients with a history of kidney disease, the risk of kidney disease needs to be monitored with regular kidney function. Evaluate kidney function per week and dose or stop taking drugs when serum phosphate concentration decreases significantly or when creatinine clearance is less than 50ml/min.

Tenofovir disoproxil fumarat may reduce bone density, so you must monitor bone density in patients with a history of fractures or a high risk of bone loss, although the effectiveness of calcium and vitamin D supplementation has not been proven, the addition may be useful for these patients. When bone abnormalities need to consult a physician.

Severe HBV outbreaks have been reported at HIV -infected patients after stopping treatment with Tenofovir. Clinical and experimental liver function should be monitored for at least a few months after stopping Tenofovir in infected patients at the same time HBV and HIV. If appropriate, should start treating HBV.

Immunously activated syndrome: In patients with HIV infected with severe immunodeficiency at the time of the beginning of the combination of antacids of Retrovirus (Cart), the inflammatory reaction may have no symptoms or opportunistic infections and cause serious clinical diseases or serious symptoms. The reactions are seen within the first few weeks at the beginning of the combination of antiviral drugs.

Be cautious with patients with renal failure, should monitor kidney function before starting treatment with tenofovir.

The effect of the drug on driving and operating machinery

No research shows the effect of the drug affects the ability to drive and operate machinery. However, patients need to be notified of the possibility of drowsiness, fatigue, headache when treated with tenofovir disoproxil fumarat.

Use drugs for women during pregnancy and lactation

Pregnant women

There is no information on the use of Tenofovir Disoproxil Fumarat during pregnancy. Tenofovir disoproxil fumarat should only be used when the benefits are proven more than the risk to the fetus.

However, due to the risk of increasing the possibility of conception unknown, the use of Tenofovir disoproxil fumarat in women of reproductive age should be accompanied by effective contraception.

breastfeeding women

There is no information on the excretion of Tenofovir Disoproxil Fumarat through breast milk. Therefore, breastfeeding women should not take the drug. According to general recommendations, HIV -infected women should not breastfeed to avoid HIV transmission to babies.

Drug interaction

Not used simultaneously with kidney toxins or substances excreted in the kidneys. If required to use, monitor weekly kidney function

Tenofovir increases the concentration of didanosine in plasma.

Do not use 3 drugs simultaneously: Tenofovir, Lamivudine with abacavir or didanosine because of the loss of treatment and causing resistance.

When using Tenofovir and Atazanavir simultaneously, the plasma concentration of Atazanavir will decrease and the tenofovir increases, the impact of reduced ritonavir. Use with Ritonavir, Lopinavir with Tenofovir will increase the level of Tenofovir in plasma.

Sharing anti -diabetes drugs Metformin with Didanosine, Stavudine, Tenofovir leads to heavy lactic acid infections.

HIV Protase inhibitors: A combination or co -operational interaction between Tenofovir and Protase inhibitors such as Amprenavir, Atazanavir, Indinavir, Ritonavir, Saquinavir.

Nucleosid -free reverse copy enzyme inhibitors: Collective or co -operations between tenofovir and nucleosid -free copy inhibitors such as Delavirdin, Efavirenz, Nevirapin.

Nucleoside reverse copy inhibitors: Collective or co -operating between tenofovir and nucleoside copy inhibitors such as abacavir, didanosin, emtricitabin, lamivudin, stavudin, zalcitabin, zidovudine.

Oral contraceptives: Unknown pharmacokinetic interaction with oral contraceptives containing ethinyl estradiol and norgestimat.

Storage

Leave a cool place, avoid light, temperatures below 30⁰C.

To be out of reach of children, read the instructions carefully before use.

Other drugs

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.